Cancer clinical trials in the region Auvergne-Rhône-Alpes
509 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Chronic myeloid leukemia (CML)
#NCT04835584
LMC Phase Chronique (phase 1b et phase 2 Bras A et B)
Required disease stage
Chronic phase
Required genetic anomalies
BCR-ABL
Ph+ (Philadelphia chromosome positive)
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded genetic anomalies
T315I
TP53
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
Kartos Therapeutics
Phase 1 / Phase 2
Chronic myeloid leukemia (CML)
#NCT06163430
#2023-507677-18-00
Required disease stage
Chronic phase
Required genetic anomalies
BCR-ABL
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
ATP pocket inhibitor
Allosteric inhibitor
Excluded previous treatments
Systemic Treatment-Naive
6 recruiting sites
Terns, Inc.
Phase 1 / Phase 2
Lymphoma
CLL & Richter's syndrome
#NCT05006716
Required histologic types
B cell lymphoma
CLL (Chronic Lymphocytic Leukemia)
Richter's syndrome
Required histologic sub types
Large B cell lymphoma
Mantel cell lymphoma
Follicular lymphoma
Marginal zone lymphoma
Waldenström lymphoma
Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
BeOne Medecines
Phase 1 / Phase 2
Liver and bile duct cancer
#NCT07291076
#2025-523602-33-00
Required histologic sub types
Hepatocellular carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Bristol-Myers Squibb
Phase 1 / Phase 2
Lung cancer
#NCT05384626
#2024-514266-39-00
Cohortes G et H (Cohortes DDI)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Multiple myeloma
#NCT05583617
#2021-005918-34
Sous étude 4 (exposition aux 3 classes thérapeutiques)
Required histologic types
Symptomatic multiple myeloma
Required central nervous system lesions
None
Required number of previous lines of therapy
1
2
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
3 recruiting sites
Hoffmann-La Roche
Phase 1 / Phase 2
Multiple myeloma
#NCT05583617
#2021-005918-34
Sous-étude 2 (Haut risque, post autogreffe)
Required histologic types
Symptomatic multiple myeloma
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Autologous stem cell transplant
Required IMWG cytogenetic prognoses
High risk
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Hoffmann-La Roche
Phase 1 / Phase 2
Breast cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
#NCT05384626
#2024-514266-39-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
AKT
ATM
BRAF
BRCA 1/2
CDK12
CHEK 1/2
ESR
FGFR
HER2
HOXB13
KRAS G12C
KRAS non G12C
MET
MSI/dMMR
NRAS
NTRK-1/2/3
PALB2
PIK3CA
PTEN
RET
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Lung cancer
#NCT05384626
#2024-514266-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ALK
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Lung cancer
#NCT06567015
#2023-510203-21-00
Partie 2 (Optimisation de la dose)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre